Good News | Azvudine Successfully Renewed in the 2024 National Reimbursable Drugs List

On Nov. 28, Genuine Biotech announced that its self-developed Azvudine Tablets (trade name: Jiebeian®) has been successfully renewed in the 2024 National Reimbursement Drug List.

Azvudine, an innovator drug in China, is a Class 1.1 innovative drug with fully independent intellectual property rights and was awarded the Golden Medal of China Patent Award. As the world's only dual-target (reverse transcriptase and viral infectivity factor) nucleoside oral drug for the treatment of HIV infection, Azvudine was approved for the indication of HIV-1 in Jul. 2021. In Jul. 2022, Azvudine was approved for marketing for the treatment of COVID-19. It is the first domestic oral drug approved for the treatment of COVID-19 in China, and has been included in the diagnosis and treatment protocol  for COVID-19 patients of China  several times, curing more than ten million patients.

Dr. Du Jinfa, Chairman, CEO and Chief Scientific Officer of Genuine Biotech, said, "In recent years, with the support of national medical insurance policies, the accessibility to Azvudine has increased rapidly, effectively benefiting a large number of patients with COVID-19 and AIDS. This successful renewal is another evidence of the innovative and clinical values of Azvudine. In the future, Genuine Biotech will continue to focus on innovative R&D as a driving force, scaling up its core technologies, accelerating the R&D of innovative drugs, and providing more and better treatment options to benefit patients worldwide."